New drug cocktail shows promise against tough cancers
NCT ID NCT05214482
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now looking at safety and how well the treatment worked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AK112 (PD-1/VEGF bispecific antibody) and AK117 (anti-CD47 antibody) with or without chemotherapy
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced solid tumors, potentially shrinking tumors and extending life.
What could go wrong
This is an early-phase trial (Phase 1/2) with a small number of participants, so results may not apply to everyone. The drugs can cause side effects like immune-related reactions or bleeding risks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, 310000, China